Investing in SomaLogic
SomaLogic, Inc. is a privately held biotechnology company with headquarters in Boulder, Colorado.
For all investment questions, please contact us.
Interested in potential investment opportunities?
SomaLogic Business News
SomaLogic Appoints Jason Cleveland, Ph.D. as Chief Technology Officer
SomaLogic Inc. today announced the appointment of Jason Cleveland, Ph.D. as the company’s chief technology officer. In this role, Dr. Cleveland will drive technological innovations that will bring the SomaScan® proteomics platform to patients around the world.
SomaLogic Expands Its Commercial Capabilities with Three New Senior Leaders
SomaLogic Inc. announced today the appointments of Angela Bakker Lee, Ph.D. as executive vice president for healthcare markets, Tracy Hervey, MBA as executive vice president for life sciences markets and David McGovern, MBA as senior vice president of marketing. In these roles, Dr. Bakker Lee, Ms. Hervey and Mr. McGovern will drive business development and marketing efforts for SomaLogic’s proprietary protein measurement technology and growing portfolio of protein-based health information products.
SomaLogic Adds $81M to Series A Financing Totaling $214M
SomaLogic, Inc. announced today that it added $81M to its current funding round with investments from a number of additional investors, for a total Series A raise of $214M. The funds raised in this round will facilitate improving, expanding and commercializing SomaLogic’s world-leading proteomic products in both the clinical and life science markets.
Study Identifies Protein Targets for Drugs that Could be Used in the Fight Against COVID-19
An international consortium led by Medical Research Council (MRC) researchers in the UK working with SomaLogic performed the largest genetic discovery of host proteins involved in SARS-CoV-2 infection or severe COVID-19. The results are being shared via an open access platform to help investigators around the world prioritize protein targets for new or repurposed drugs to treat COVID-19. The information may also help medical researchers identify patients who are more likely to develop a serious case of COVID-19.
First Tests Launched in Japan Using SomaLogic’s SomaSignal™ Models
FonesLife Corporation, a subsidiary of NEC Solution Innovators, Ltd. of Japan, announced today that they will begin offering blood-based health tests built on the SomaLogic SomaScan® Platform to consumers in Japan. The tests, which deliver health-management information based on large-scale measurements of an individual’s blood proteins, are expected to help assess health and promote wellness in Japan’s rapidly aging population.
SomaLogic Closes $121M Series A Financing Led by Casdin Capital
SomaLogic, Inc., global leader in proteomic discovery and applications transforming biomedical discovery and clinical diagnostics, announced today that the Company has successfully closed an Initial Series A capital raise of $121 Million. The Company anticipates that additional closings will occur within the next 90 days.
SomaLogic Announces New Collaboration with FDA to Advance Biosimilar Development
SomaLogic, Inc. announced today an agreement with the US Food and Drug Administration (FDA)’s Division of Applied Regulatory Science to evaluate the utility of large-scale analysis of proteins (proteomics) for the identification of biomarkers that may be useful in demonstrating biosimilarity of a proposed biosimilar to a reference biologic.
SomaLogic Awarded Grant from National Science Foundation Convergence Accelerator
SomaLogic, Inc. announced today that a collaborative project between SomaLogic scientists and academic researchers has received a $1 million dollar Phase 1 grant from the National Science Foundation (NSF) Convergence Accelerator program. The team will apply recent advances in quantum sensing to improve methods for proteomic screening.
SomaLogic Announces New Agreement with Amgen to Accelerate Drug Discovery and Development Efforts through Comprehensive Proteomic Profiling
SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogic’s proprietary proteomics technology to help advance Amgen’s drug discovery and development programs. The agreement builds upon SomaLogic’s existing collaboration with deCODE genetics, an Amgen subsidiary based in Iceland, and will include broader application across Amgen’s pipeline.
SomaLogic Releases New SomaSignal™ Tests for NASH and NAFLD Research
SomaLogic announced today that it has added a new set of four research use only (RUO) SomaSignal™ tests that can diagnose all four components of non-alcoholic steatohepatitis (NASH) without the need for an invasive liver biopsy.
For all the latest SomaLogic news, please visit our News and Events page.